dadang n

dadang n

Innovative drug development leveraging Gut-Brain axis for natural medicine efficacy and safety.

HQ location
Suwon, South Korea
Website
Employees
Enterprise value
$10—15m
  • Edit
Get premium to view all results
DateInvestorsAmountRound
-investor

€0.0

round
*

KRW3.0b

Late VC
Total Funding000k
More about dadang n
Made with AI
Edit

DDNbio is a pioneering company in the field of drug development, focusing on the Gut-Brain axis to enhance the efficacy and safety of natural medicines. The company operates in the pharmaceutical and health functional food markets, serving clients who are looking for innovative and safe long-term medication solutions. DDNbio's business model revolves around the development of specialized drugs for various diseases through biomarker analysis and the regulation of intestinal microorganisms and the immune system. This approach allows the company to create drugs that are not only effective but also safe for long-term use. Revenue is generated through the development and commercialization of these specialized drugs and health functional foods. The company also engages in clinical trials to validate the effectiveness and safety of its products, ensuring they meet regulatory standards.

Keywords: Gut-Brain axis, natural medicines, drug development, biomarkers, intestinal microorganisms, immune system, long-term medication, clinical trials, health functional foods, pharmaceutical innovation.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads